Jci_page_head_homepage_01 Jci_page_head_homepage_02
Paul T. Brinkkoetter, Paul Olivier, Jimmy S. Wu, Scott Henderson, Ronald D. Krofft, Jeffrey W. Pippin, David Hockenbery, James M. Roberts, Stuart J. Shankland
Published in Volume 119, Issue 10
J Clin Invest. 2009; 119(10):3089–3101 doi:10.1172/JCI37978
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Cyclin I is a specific binding partner and activator of Cdk5 in HEK293 cells.

(A) Following cotransfection of HEK293 cells with myc-tagged cyclin I and HA-tagged Cdks1–6, cyclin I coimmunoprecipitated with Cdk 3–6. (B, C) To assess which Cdk was activated by cyclin I, immunoprecipitations were performed followed by histone H1 (B) or Rb (C) kinase assays. Kinase activity was only detected in cells cotransfected with cyclin I and Cdk5. HA-Cdk2 and myc–cyclin E (B, histone H1 assay) and HA-Cdk4 and myc–cyclin D (C, Rb assay) served as positive controls. These results show that cyclin I specifically activates Cdk5, but not Cdk1, -2, -3, -4, or -6. (D) To prove specificity, HEK293 cells were cotransfected with cyclin I alone, cyclin I and Cdk5, or cyclin I and a dominant negative Cdk5 (D145N-Cdk5). No kinase activity was detected when cells were transfected with cyclin I alone (lane 1). Kinase activity was detected in cells transfected with cyclin I and Cdk5 (lane 2), but not in cells with cyclin I and the kinase-inactive mutant (lane 3). (E) No histone H1 kinase activity was detected when control IgG was used for immunoprecipitation (lane 1). Following immunoprecipitation with an antibody to myc, kinase activity was present (lane 2). In the presence of the Cdk inhibitors olomoucine (10 μM; lane 3) and roscovitine (50 μM, lane 4), kinase activity was reduced. The controls DMSO and PD98059 (an ERK5 inhibitor) had no effect on cyclin I kinase activity.